The National Cancer Institute's perspective and agenda for promoting awareness and research on alternative therapies for cancer

Journal of Alternative and Complementary Medicine

Volumn 8, Issue 5, 2002, Pages 545-550

  White, Jeffrey D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE MEDICINE; CANCER RESEARCH; CANCER THERAPY; CONFERENCE PAPER; HEALTH CARE PERSONNEL; HERBAL MEDICINE; LEISURE; LIFESTYLE; MEDICAL PRACTICE; NUTRITION; PRIORITY JOURNAL; PSYCHOLOGY;

EID: 0036805458     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/107555302320825048     Document Type: Conference Paper

References (25)

1. Dietary Treatments. In: Unconventional Cancer Treatments. Office of Technology Assessment, Washington, D.C., 1990a:75-81.
2. Herbal Treatments. In: Unconventional Cancer Treatments. Office of Technology Assessment: Washington, D.C., 1990b:44-51.
3. Beliveau R, Delbecchi L, Beaulieu E, Kachra Z. AE-941: A potent inhibititor of matrix metalloproteinase [abstr 3026]. Proceedings of the American Association for Cancer Research, 1999;40:458.
4. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early stage breast cancer. N Engl J Med 1999;340:1733-1739.
5. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979;301:687-690.
6. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 1998;280:1569-1575.
7. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993;328:246-252.
8. Evans WK, Latreille J, Barist G, Falardeau P, Champagne P, Riviere M, DuPont E. AE-941, an inhibitor of angiogenesis: Rationale for development in combination with induction chemotherapy/radiotherapy in patients with non-small-cell lung cancer (NSCLC) [abstr 992]. Eur J Cancer 1999;35(suppl4):S250.
9. Fernandez CV, Stutzer CA, MacWilliam L, Fryer C. Alternative and complementary therapy use in pediatric oncology patients in British Columbia: Prevalence and reasons for use and nonuse. J Clin Oncol 1998;16: 1279-1286.
10. Folkman J. The vascularization of tumors. Sci Am 1976;234:58-64, 70-73.
11. Gonzalez NJ, Isaacs LL. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. Nutr Cancer 1999;33:117-124.
12. Gotay CC, Hara W, Issell BF, Maskarinec G. Use of complementary and alternative medicine in Hawaii cancer patients. Hawaii Med J 1999;58:94-98.
13. Hawkins MJ, Friedman MA. National Cancer Institute's evaluation of unconventional cancer treatments. J Natl Cancer Inst 1992;84(22):1699-1702.
14. Kosty MP, Fleishman SB, Herndon JE, Coughlin K, Kornblith AB, Scalzo A, Morris JC, Mortimer J, Green MR. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: A randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994;12:1113-1120.
15. Lee A, Langer R. Shark cartilage contains inhibitors of tumor angiogenesis. Science 1983;221:1185-1187.
16. Loprinzi CL, Goldberg RM, Su JQ, Mailliard JA, Kuross SA, Maksymiuk AW, Kugler JW, Jett JR, Ghosh C, Pfeifle DM, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994a;12:1126-1129.
17. Loprinzi CL, Kuross SA, O'Fallon JR, Gesme DH, Gerstner JB, Rospond RM, Cobau CD, Goldberg RM. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994b;12:1121-1125.
18. Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 1998;16:3649-3655.
19. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985;312:137-141.
20. Moertel CG, Fleming TR, Rubin J, Kvols LK, Sarna G, Koch R, Currie VE, Young CW, Jones SE, Davignon JP. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 1982;306:201-206.
21. Oikawa T, Ashino-Fuse H, Shimamura M, Koide U, Iwaguchi T. A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis. Cancer Lett 1990;51:181-186.
22. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-2514.
23. Sparber A, Bauer L, Curt G, Eisenberg D, Levin T, Parks S, Steinberg SM, Wootton J. Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum 2000;27:623-630.
24. White JD. Complementary, alternative, and unproven methods of cancer treatment. In: Cancer: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Vol. 2. Philadelphia: Lippincott Williams & Wilkins, 2001:3147-3157.
25. Workshop on Alternative Medicine. Alternative Medicine: Expanding Medical Horizons. A Report to the National Institutes of Health on Alternative Medical Systems and Practices in the United States. Chantilly, VA: Workshop on Alternative Medicine, 1992.